PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode
PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more costโeffective GEP test compared with Oncotype DX at a threshold willingnessโtoโpay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Read More
Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance
PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retรจl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Read More
Impact of Mammographic Screening on the Detection of Good and Poor Prognosis Breast Cancers
PUBLICATION: Breast Cancer Res Treat. 2011 Dec;130(3):725-34. doi: 10.1007/s10549-011-1748-z. Epub 2011 Sep 4. AUTHORS: Esserman L.J., Shieh Y., Rutgers E.J., Knauer M., Retรจl V.P., Mook S., Glas A.M., Moore D.H., Linn S., van Leeuwen F.E., van 't Veer L.J. SUMMARY: In women aged 49-60, the time period of diagnosis significantly Read More
The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase
PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742โ2749. AUTHORS: Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van โt Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso Read More
Use of a Genomic Test (MammaPrintโข) in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
PUBLICATION: Arch Gynecol Obstet (2011) 283: 597. https://doi.org/10.1007/s00404-010-1454-9. AUTHORS: Kunz, G. SUMMARY: 44 patients had MammaPrint results and were eligible for the analysis. The results revealed a low risk result in 29 patients and a high risk result in 15 patients. Read more: Kunz_2011_Arch Gynecol Obstet._Use of a Genomic Test Read More
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue
PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher L., de Ronde J.J., Nieuwland M., Kerkhoven R.M., Simon I., Rutgers E.J., Wessels L.F., Van't Veer L.J. SUMMARY: We demonstrate that data generated from FFPE material with the DASL assay, if properly processed, are comparable to data extracted from the Read More
Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer
PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use Read More
